Format

Send to

Choose Destination
Clin Lymphoma Myeloma Leuk. 2015 May;15(5):292-7. doi: 10.1016/j.clml.2014.11.001. Epub 2014 Nov 15.

Real-life experience of a brief arsenic trioxide-based consolidation chemotherapy in the management of acute promyelocytic leukemia: favorable outcomes with limited anthracycline exposure and shorter consolidation therapy.

Author information

1
Blood and Marrow Transplant Program, Northside Hospital, Atlanta, GA.
2
Department of Oncology, Johns Hopkins University, Baltimore, MD.
3
Department of Mathematics and Statistics, Georgia State University, Atlanta, GA.
4
Leukemia Program, Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH.
5
Section of Hematology, Department of Internal Medicine, Yale University, New Haven, CT.
6
Section of Hematology, Department of Internal Medicine, Yale University, New Haven, CT. Electronic address: amer.zeidan@yale.edu.

Abstract

BACKGROUND:

Anthracyclines have activity against acute promyelocytic leukemia (APL) but can cause cardiac toxicity and secondary malignancy. The all-trans retinoic acid (ATRA)-arsenic trioxide (ATO) combination is an effective noncytotoxic approach for APL. However, its efficacy against high-risk APL (white blood cell count > 10,000/μL) has not been documented. Also, it requires ≥ 8 months to complete therapy.

PATIENTS AND METHODS:

We report a retrospective analysis of 63 patients with APL given one cycle of ATO-based consolidation chemotherapy.

RESULTS:

The 5-year overall survival, event-free survival, and leukemia-free survival was 93% (95% confidence interval [CI], 82%-97%), 89% (95% CI, 77%-95%), and 92% (95% CI, 80%-97%), respectively.

CONCLUSION:

These data have confirmed that an abbreviated ATO-based chemotherapy regimen is an effective consolidation therapy for APL, including high-risk APL, and can be completed within 4 months.

KEYWORDS:

APL; ATO; All-trans retinoic acid; Anthracyclines; Promyelocytic leukemia-retinoic acid receptor α

PMID:
25499624
PMCID:
PMC4409502
DOI:
10.1016/j.clml.2014.11.001
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center